PMID- 25102912
OWN - NLM
STAT- MEDLINE
DCOM- 20151117
LR  - 20211021
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 4
DP  - 2014 Aug 8
TI  - Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death 
      receptor 5 of human colon cancer cells.
PG  - 6000
LID - 10.1038/srep06000 [doi]
LID - 6000
AB  - A combined therapy of sulindac sulfide and tumor necrosis factor-related 
      apoptosis-inducing ligand (TRAIL) is a promising strategy for the treatment of 
      cancer. Sulindac sulfide had been shown to induce the expression of death 
      receptor 5 (DR5), a receptor for TRAIL, and sensitize cancer cells to 
      TRAIL-induced apoptosis; however, the molecular mechanism underlying the 
      upregulation of DR5 has not yet been elucidated. We demonstrate here that myeloid 
      zinc finger 1 (MZF1) mediates the induction of DR5 by sulindac sulfide. Sulindac 
      sulfide induced the expression of DR5 at the protein and mRNA levels in colon 
      cancer SW480 cells. Furthermore, sulindac sulfide increased DR5 promoter 
      activity. We showed that sulindac sulfide stimulated DR5 promoter activity via 
      the -301 to -253 region. This region contained a putative MZF1-binding site. 
      Site-directed mutations in the site abrogated the enhancement in DR5 promoter 
      activity by sulindac sulfide. MZF1 directly bound to the putative MZF1-binding 
      site of the DR5 promoter and the binding was increased by sulindac sulfide. The 
      expression of MZF1 was also increased by sulindac sulfide, and MZF1 siRNA 
      attenuated the upregulation of DR5 by sulindac sulfide. These results indicate 
      that sulindac sulfide induces the expression of DR5 by up-regulating MZF1.
FAU - Horinaka, Mano
AU  - Horinaka M
AD  - 1] Department of Molecular-Targeting Cancer Prevention, Graduate School of 
      Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, 
      Kamigyo-ku, Kyoto 602-8566, Japan [2].
FAU - Yoshida, Tatsushi
AU  - Yoshida T
AD  - 1] Department of Molecular-Targeting Cancer Prevention, Graduate School of 
      Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, 
      Kamigyo-ku, Kyoto 602-8566, Japan [2].
FAU - Tomosugi, Mitsuhiro
AU  - Tomosugi M
AD  - Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical 
      Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, 
      Kamigyo-ku, Kyoto 602-8566, Japan.
FAU - Yasuda, Shusuke
AU  - Yasuda S
AD  - Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical 
      Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, 
      Kamigyo-ku, Kyoto 602-8566, Japan.
FAU - Sowa, Yoshihiro
AU  - Sowa Y
AD  - Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical 
      Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, 
      Kamigyo-ku, Kyoto 602-8566, Japan.
FAU - Sakai, Toshiyuki
AU  - Sakai T
AD  - Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical 
      Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, 
      Kamigyo-ku, Kyoto 602-8566, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140808
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 0 (MZF1 protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Receptors, TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (TNF-Related Apoptosis-Inducing Ligand)
RN  - 184SNS8VUH (Sulindac)
RN  - 6UVA8S2DEY (sulindac sulfide)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/drug effects
MH  - Binding Sites
MH  - Cell Line, Tumor
MH  - Colonic Neoplasms/metabolism/pathology
MH  - DNA Fragmentation/drug effects
MH  - HCT116 Cells
MH  - Humans
MH  - Kruppel-Like Transcription Factors/antagonists & inhibitors/genetics/*metabolism
MH  - Mutagenesis, Site-Directed
MH  - Promoter Regions, Genetic
MH  - RNA Interference
MH  - RNA, Messenger/metabolism
MH  - RNA, Small Interfering/metabolism
MH  - Receptors, TNF-Related Apoptosis-Inducing Ligand/genetics/*metabolism
MH  - Sulindac/*analogs & derivatives/pharmacology
MH  - TNF-Related Apoptosis-Inducing Ligand/pharmacology
MH  - Up-Regulation/*drug effects
PMC - PMC4126006
EDAT- 2014/08/12 06:00
MHDA- 2015/11/18 06:00
PMCR- 2014/08/08
CRDT- 2014/08/09 06:00
PHST- 2014/02/26 00:00 [received]
PHST- 2014/07/22 00:00 [accepted]
PHST- 2014/08/09 06:00 [entrez]
PHST- 2014/08/12 06:00 [pubmed]
PHST- 2015/11/18 06:00 [medline]
PHST- 2014/08/08 00:00 [pmc-release]
AID - srep06000 [pii]
AID - 10.1038/srep06000 [doi]
PST - epublish
SO  - Sci Rep. 2014 Aug 8;4:6000. doi: 10.1038/srep06000.